Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Convergence 2020 has come and gone, but you can still access recorded sessions, which are available to attendees until 31 December 2020.
Replay the moments of Euro Convergence 2020. Recorded sessions are available to attendees until 31 January 2020.
RAPS' “how to” guide to developing a comprehensive global regulatory strategy for all types of medical devices. Updated September 2020.
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
Posted 08 April 2016 | By Zachary Brennan
The European Medicines Agency (EMA) this week began running a series of pharmacovigilance training sessions to help companies and regulators meet their obligations when using EudraVigilance, a centralized European database of suspected adverse reactions to medicines in the European Economic Area (EEA).
At least one user from each national competent authority, marketing-authorization holder or sponsor of clinical trials in the EEA should complete the training to ensure the information collected in EudraVigilance is of the highest quality and integrity, EMA said.
Those who successfully complete the currently available EudraVigilance training courses and the subsequent registration process will be able to start the electronic submission of individual case safety reports (ICSRs) and ICSR acknowledgements to meet their reporting obligations in relation to pharmacovigilance or clinical trials authorized in the EEA.
Currently there are two sets of three-day training courses. One set will help participants understand ICH rules for safety reporting; understand EudraVigilance better; understand how to electronically transmit ICSRs, as well as how to search and download safety reports, among other tasks. In addition to this week’s course in Madrid, the next courses are occurring:
EMA is also holding a set of EudraVigilance Data Analysis System (EVDAS) training courses for national competent authorities in EEA member states.
Later this year and next year, the EMA will release a set of training modules focusing on pharmacovigilance. EMA has developed the new curriculum to prepare stakeholders for the changes introduced by the 2010 pharmacovigilance legislation regarding adverse reaction reporting and signal detection.
EMA advises stakeholders to start their training around six months before the agency implements the new EudraVigilance functionalities, and to plan regular refresher training sessions in the run-up to implementation.
EudraVigilance Training
Tags: EMA, pharmacovigilance, EudraVigilance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.